Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

La Jolla Institute validates Type 1 diabetes computer model's predictive success through lab testing

09.12.2010
Team finds new software accurately predicts key information on nasal insulin treatment

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab® Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

The findings, which also showed the platform's ability to predict critical type 1 diabetes molecular "biomarkers," were published in the December issue of the scientific journal Diabetes, and further validate the importance of the new model as a valuable research tool in type 1 diabetes. The software is designed to enable researchers to rapidly streamline laboratory research through the evaluation of alternative scenarios for therapeutic strategies that show the most promise for working in humans.

"Since laboratory studies can cost hundreds of thousands of dollars, and early stage human clinical trials can cost $10 million dollars or more, predicting the right conditions to try is important," said Dr. von Herrath, director of the Type 1 Diabetes Research Center at the La Jolla Institute for Allergy & Immunology, where the studies were conducted.

"We've found that using this in silico (computer analysis) prediction platform can quicken the pace and effectiveness of type 1 diabetes research," he continued. "By allowing us to pre-test our theories in computer models, we can ensure that the more time-intensive and costly process of laboratory testing is focused on the most promising therapeutic strategies, with the greatest chance of success."

The platform, developed by Entelos Inc., a life sciences company specializing in predictive technologies, has previously been shown to successfully predict various data from published type 1 diabetes experiments. Dr. von Herrath's team used a different approach to test the model, asking it to predict the outcome of a hypothetical experiment on nasal insulin dosing frequency in animal models that had not yet been performed. The prediction was then tested in the laboratory, where its results were confirmed.

In addition, he said, the model was able to accurately identify the particular time frame at which key type 1 diabetes "biomarkers" kicked in. Biomarkers are specific cell types or proteins that tell researchers at what point a therapeutic option is working or when it is time to start treatment. In the case of the La Jolla Institute study, the model successfully predicted the onset of biomarkers indicating beta cell protection in the NOD mouse.

"The model accurately predicted that implementing a low frequency nasal insulin dosing regimen in animal models was more beneficial in controlling type 1 diabetes than a high frequency regimen," said Dr. von Herrath, noting that the software's prediction of the biomarkers was key in this process. "These results confirmed our hypotheses on the benefits of low-frequency nasal insulin dosing. But even more importantly, the advantage of applying computer modeling in optimizing the therapeutic efficacy of nasal insulin immunotherapy was confirmed."

The results were reported in the paper "Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency To Be Crucial for Diabetes Protection." Dr. von Herrath was senior author on the paper and La Jolla Institute scientist Georgia Fousteri, Ph.D., and Jason Chan, Ph.D., from Entelos' R&D group, were first co-authors.

The Type 1 Diabetes PhysioLab® Platform is a large-scale mathematical model of disease pathogenesis based on non-obese diabetic (NOD) mice. The platform was developed with input from an independent scientific team of leading type 1 diabetes experts. The research support group of the American Diabetes Association funded the work of the software's development to provide a new scientific tool for enhancing the speed and effectiveness of type 1 diabetes research.

More than 400,000 children worldwide suffer from type 1 diabetes, a chronic disease that can lead to severe complications, such as blindness, cardiovascular disease, renal disease, coma or even death.

The platform, developed over two years, simulates autoimmune processes and subsequent destruction of pancreatic beta cells from birth through frank diabetes onset (hyperglycemia). The destruction of insulin-producing beta cells in the pancreas is the underlying cause of type 1 diabetes.

Specifically, Dr. von Herrath's team employed the model to investigate the possible mechanisms underlying the effectiveness of nasal insulin therapy, using the B: 9-23 peptide. "The experimental aim was to evaluate the impact of dose, frequency of administration and age at treatment on key molecular mechanisms and optimal therapeutic outcome," he said.

Using parameters input by the scientific team, the model accurately predicted that less frequent doses of nasal insulin, started at an early disease stage, would protect more effectively against beta cell destruction than higher frequency doses in NOD mice.

Dr. von Herrath added that the positive results add credence to the idea of creating computer models for analyzing therapeutic interventions in human disease. "These results support the development and application of humanized platforms for the design of clinical trials," he said.

About La Jolla Institute

Founded in 1988, the La Jolla Institute for Allergy & Immunology is a biomedical research nonprofit focused on improving human health through increased understanding of the immune system. Its scientists carry out research seeking new knowledge leading to the prevention of disease through vaccines and the treatment and cure of infectious diseases, cancer and autoimmune diseases such as rheumatoid arthritis, type 1 (juvenile) diabetes, Crohn's disease and asthma. La Jolla Institute's research staff includes more than 100 Ph.D.s and M.D.s. For more information, go to www.liai.org

Bonnie Ward | EurekAlert!
Further information:
http://www.liai.org

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>